A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer

Contact:

NCT Number:

Protocol:

AAAT7374

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

This study is being done to answer the following question: Can abemaciclib and olaparib be taken safely together in ovarian cancer that has come back? We are asking you to take part in this research study because you have ovarian cancer that has come back. We are trying to determine whether abemaciclib and olaparib can be taken safely and tolerably together in ovarian cancer that has come back.

Are you Eligible? (Inclusion Criteria)

  • Must have ovarian cancer that has come back within 6 months of last dose of treatment.
  • Must have received 1-3 prior treatment regimens.
  • Must have lesions seen on CT scan or MRI.

Specialty Area(s)

Gynecologic Cancers, Ovarian Cancer

Principal Investigator

Profile Headshot
  • Chief, Division of Gynecologic Oncology
  • Vice Chair of Academic Affairs, Department of Obstetrics and Gynecology

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032